<DOC>
	<DOC>NCT02119234</DOC>
	<brief_summary>The study is performed to investigate the effect of the spacing device on the pharmacokinetics of CHF 5993 pMDI active ingredients administered with and without Aerochamber Plus Flow-vu antistatic VHC spacer as a single administration in COPD patients. Moreover, the general safety and tolerability of the treatments will be evaluated.</brief_summary>
	<brief_title>Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>COPD patients smokers or exsmokers postbronchodilator FEV1 between 30 and 60% of predicted value Positive serology to HIV and hepatitis Known respiratory disorder other than COPD Recent COPD exacerbations or hospitalization for COPD Treatment with nonpermitted concomitant medication clinically relevant concomitant disease clinically relevant abnormal laboratory or ECG parameters</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>